Gabapentin Tablet
Product Images NDC 71610-767

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71610-767). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 600 mg (71610 0767 30)

Gabapentin USP 600 mg oral tablets packaging label showing 30 tablets per bottle. The label includes storage instructions, manufacturer ScieGen Pharmaceuticals Inc., Hauppauge, NY, and repackager Aphena Pharma, Cookeville, TN. The product NDC 71610-0767-30 is displayed along with barcode and batch information.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Figure 1 (Image 01)

A line graph showing mean pain score over an 8-week period comparing placebo to Gabapentin at 3600 mg/day. The x-axis represents weeks from baseline to week 8, and the y-axis represents mean pain scores from 0 to 10. The graph includes a 4-week dose titration period followed by a 4-week fixed dose period, illustrating a decrease in mean pain score with Gabapentin compared to placebo.*

FDA Label Image

Figure 2 (Image 02)

A line graph showing mean pain scores over seven weeks for three groups: placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis represents weeks, including a 3-week dose titration period followed by a 4-week fixed dose period, while the y-axis displays mean pain scores from 0 to 10. Pain scores decrease more in the Gabapentin groups compared to placebo over time.*

FDA Label Image

Figure 3 (Image 03)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and gabapentin (GBP) at doses of 1800 mg, 2400 mg, and 3600 mg across two studies. The chart shows percentage responder values for each group, with statistical significance indicated by asterisks.*

FDA Label Image

Image-04 (Image 04)

An equation representing the calculation for creatinine clearance (CLCr) based on age, weight, serum creatinine, and a gender adjustment factor. The formula is displayed in a mathematical layout typically used in pharmacokinetics or clinical dosing calculations.*

FDA Label Image

Gabapentin Structural Formula (Image 05)

Chemical structure of Gabapentin showing a cyclohexane ring with attached amino and carboxymethyl groups, representing its molecular composition.*

FDA Label Image

Image-09 (Image 09)

A scatter plot showing the percentage difference on the y-axis and daily dose in milligrams on the x-axis for Gabapentin. The data points represent three studies labeled as Study a, Study b, and Study c, showing differences at doses of 600 mg, 900 mg, 1200 mg, and 1800 mg.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.